Search results
Results from the WOW.Com Content Network
The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...
The synthesis of gliflozins involves three general steps. The first one is the construction of the aryl substituent, the next one is the introduction of the aryl moiety onto the sugar or glucosylation of the aryl substituent and the last one the deprotection and modification of the arylated anomeric center of the sugar. [52]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...
[4] [17] [12] Hypertensive disorders of pregnancy (which include pre-eclampsia) are one of the most common causes of death due to pregnancy. [6] They resulted in 46,900 deaths in 2015. [ 7 ] Pre-eclampsia usually occurs after 32 weeks; however, if it occurs earlier it is associated with worse outcomes. [ 6 ]
Troglitazone (Rezulin), withdrawn due to increased incidence of drug-induced hepatitis. Balaglitazone – developed by Dr Reddy's Laboratories, discontinued during 2010-11 phase III trials as no better than available molecules. AS-605240 [648450-29-7] Replacing one oxygen atom in a thiazolidinedione with an atom of sulfur gives a rhodanine.
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage).